Comprehensive guide to Epidiolex (CBD) for treating childhood epilepsy
Epidiolex, the first FDA-approved plant-derived CBD medication, significantly reduces seizures in Dravet and Lennox-Gastaut syndromes but has important side effects and drug interactions that require careful management.
Quick Facts
What This Study Found
Epidiolex was FDA-approved June 2018 for patients aged 2+ with Dravet or Lennox-Gastaut syndrome. Common side effects include somnolence, decreased appetite, and diarrhea. Significant drug interactions occur with clobazam (increased active metabolite levels) and valproate (hepatotoxicity risk). CBD is metabolized primarily by CYP3A4 and CYP2C19, creating numerous potential interactions with other antiepileptic drugs.
Key Numbers
FDA approved June 25, 2018. Approved for ages 2+. Metabolized by CYP3A4 and CYP2C19. Significant interactions with clobazam and valproate.
How They Did This
State-of-the-art review covering CBD history, pharmacology, toxicology, clinical evidence, side effects, and drug-drug interactions in epilepsy.
Why This Research Matters
Patients with Dravet and Lennox-Gastaut syndromes have limited treatment options. Understanding both the benefits and the interaction risks of Epidiolex is essential for safe prescribing.
The Bigger Picture
As the first plant-derived CBD product with FDA approval, Epidiolex bridges the gap between medical cannabis and conventional pharmaceuticals, but its complex interactions highlight the importance of pharmaceutical oversight.
What This Study Doesn't Tell Us
Limited long-term efficacy and safety data. Drug interaction studies are ongoing. Review reflects knowledge at time of publication.
Questions This Raises
- ?Will long-term CBD use in children reveal new safety concerns?
- ?Can dosing strategies minimize hepatotoxicity risk when combined with valproate?
Trust & Context
- Key Stat:
- First FDA-approved plant-derived CBD medication
- Evidence Grade:
- Comprehensive review of randomized controlled trial data supporting FDA approval.
- Study Age:
- 2020 review of product approved in 2018.
- Original Title:
- Emerging Use of Epidiolex (Cannabidiol) in Epilepsy.
- Published In:
- The journal of pediatric pharmacology and therapeutics : JPPT : the official journal of PPAG, 25(6), 485-499 (2020)
- Authors:
- Abu-Sawwa, Renad, Scutt, Brielle, Park, Yong(2)
- Database ID:
- RTHC-02370
Evidence Hierarchy
Summarizes existing research on a topic.
What do these levels mean? →Frequently Asked Questions
What is Epidiolex used for?
Epidiolex is an FDA-approved purified CBD medication for patients aged 2 and older with Dravet syndrome or Lennox-Gastaut syndrome, two severe forms of childhood epilepsy.
Does Epidiolex interact with other seizure medications?
Yes, significant interactions occur with clobazam (increasing sedation) and valproate (increasing liver toxicity risk). CBD is metabolized by CYP3A4 and CYP2C19, creating potential interactions with many other drugs.
Read More on RethinkTHC
- CBD-oil-quality-guide
- anxiety-medication-after-quitting-weed
- cannabis-chemotherapy-nausea
- cannabis-chronic-pain-research
- cannabis-epilepsy-CBD-Epidiolex
- cbd-anxiety-research-evidence
- cbd-for-weed-withdrawal
- cbd-vs-thc-difference
- medical-benefits-of-cannabis
- quitting-weed-before-surgery
- quitting-weed-medication-interactions
- quitting-weed-pregnancy
- quitting-weed-pregnant
- seniors-older-adults-cannabis-risks-medications
- weed-breastfeeding-THC-breast-milk
Cite This Study
https://rethinkthc.com/research/RTHC-02370APA
Abu-Sawwa, Renad; Scutt, Brielle; Park, Yong. (2020). Emerging Use of Epidiolex (Cannabidiol) in Epilepsy.. The journal of pediatric pharmacology and therapeutics : JPPT : the official journal of PPAG, 25(6), 485-499. https://doi.org/10.5863/1551-6776-25.6.485
MLA
Abu-Sawwa, Renad, et al. "Emerging Use of Epidiolex (Cannabidiol) in Epilepsy.." The journal of pediatric pharmacology and therapeutics : JPPT : the official journal of PPAG, 2020. https://doi.org/10.5863/1551-6776-25.6.485
RethinkTHC
RethinkTHC Research Database. "Emerging Use of Epidiolex (Cannabidiol) in Epilepsy." RTHC-02370. Retrieved from https://rethinkthc.com/research/abu-sawwa-2020-emerging-use-of-epidiolex
Access the Original Study
Study data sourced from PubMed, a service of the U.S. National Library of Medicine, National Institutes of Health.
This study breakdown was produced by the RethinkTHC research team. We analyze and report published research findings without making health recommendations. All interpretations are based solely on the published abstract and study data.